Medscape2h
Bone-Derived Hormone Predicts Diabetic Kidney Disease Risk
Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, a recent observational study found.
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...
Verywell Health16h
6 Essential Nutrients That Can Improve Your Eye Health
Can supplementing with vitamins and minerals protect your eye health? Learn more about the role of nutrients in age-related ...
USA News Group: FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary - Weeks after the monumental ...
Avant Technologies and Ainnova Advance Toward FDA Clinical Trial with Selection of Top CRO
LAS VEGAS, NV / / February 11, 2025 / Avant Technologies, Inc. (OTCQB:AVAI) ('Avant' or the 'Company'), and its partner, Ainnova Tech, Inc., (Ai ...
Ozempic blindness: New study flags unexpected side effect of weight loss drugs
A new study published in JAMA Ophthalmology reveals that weight loss drugs like Ozempic and similar medications could cause ...
Goldman Sachs cuts Regenxbio stock rating, slashes price target
Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...